Attovia Therapeutics
ATTO · NASDAQ
$13.83−$0.67 (−4.62%)TodayMarket closed ·
Prev close $14.50
Who owns ATTO
Largest institutional holders, from their latest 13F filings
The 9 largest institutions hold 42.0% of ATTO’s shares.
- Frazier Life Sciences Management, L.P.13.5%
- Deep Track Capital LP11.3%
- VenBio Partners LLC8.3%
- Alamar HoldCo, LLC.7.1%
- Next 5 largest institutions1.8%
- All other shareholders58.0%
| Holder | Shares | % of shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 6.15M | 13.48% |
| Deep Track Capital LP | 5.16M | 11.31% |
| VenBio Partners LLC | 3.80M | 8.32% |
| Alamar HoldCo, LLC. | 3.23M | 7.07% |
| Fu (Tao) | 548.56K | 1.20% |
| Veiby (Petter) | 104.95K | 0.23% |
| Odrowaz (Zaneta Ph.D.) | 103.27K | 0.23% |
| You (Angie J. Ph.D.) | 52.85K | 0.12% |
| Chen (Hubert M.D.) | 2.96K | 0.01% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $77.44M (25 trades) and sold $9.01M (92 trades) of ATTO on the open market.
| Insider | Type | Shares | Value |
|---|---|---|---|
| WALSH COLIN | Other | 4.45M | — |
| WALSH COLIN | Other | 18.18M | — |
| WALSH COLIN | Buy | 500.00K | $8.50M |
| WALSH COLIN | Other | 478.50K | — |
| WALSH COLIN | Other | 1.96M | — |
| GOLDMAN SACHS GROUP INC | Other | 4.45M | — |
| GOLDMAN SACHS GROUP INC | Other | 18.18M | — |
| GOLDMAN SACHS GROUP INC | Buy | 500.00K | $8.50M |
| GOLDMAN SACHS GROUP INC | Other | 478.50K | — |
| GOLDMAN SACHS GROUP INC | Other | 1.96M | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 1.65M
- Days to cover
- 2.98
- % of shares outstanding
- 3.61%
- Average daily volume
- 553.84K
- Change since last report
- +98.5%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.